Skip to search formSkip to main contentSkip to account menu

CXCR4 Inhibitor X4P-001

Known as: (S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine, X4P-001 
An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
4510Background: X4P-001 is an oral, selective, allosteric inhibitor of the chemokine receptor CXCR4, which is a promising novel… 
2017
2017
896PA Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)
2016
2016
MDSC trafficking and function in RCC by CXCR4 in the presence of a VEGF-R antagonist is dependent on HIF-2α expression
2016
2016
Méthodes pour le traitement d'une maladie immunodéficiente
La presente invention concerne des methodes de traitement de patients atteints du syndrome WHIM ou de troubles associes, tels que… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)